Physician profile
Glen Scott
NPI 1184656233
$12,050.43
in general payments reported to CMS, 2019-2025
71 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,117 · 2020: $2,120 · 2021: $1,999 · 2022: $2,005 · 2023: $1,429 · 2024: $788 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,783 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,782.94 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $891.68 | 2019-2022 | |
| Eisai INC. | $692.55 | 2019-2025 | |
| Abbvie INC. | $665.90 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $611.99 | 2019-2024 | |
| Biogen, INC. | $510.56 | 2019-2023 | Vumerity, Tysabri |
| Argenx US, INC. | $494.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $472.68 | 2019-2024 | Mavenclad |
| Ucb, INC. | $471.89 | 2019-2025 | Rystiggo, Fintepla, Nayzilam |
| Alexion Pharmaceuticals, INC. | $470.47 | 2019-2024 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $451.13 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $439.86 | 2019-2025 | Nuplazid |
| Csl Behring | $437.03 | 2019-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $420.32 | 2019-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $340.53 | 2019-2023 | Ongentys, Ingrezza |
| Genentech USA, INC. | $329.26 | 2019-2023 | Ocrevus, Enspryng |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.